Figure 3. Genomic differences of the three sub-clusters of colon cancer cell lines suggest the different response to BRAF inhibitors and PI3K-mTOR inhibitors treatment. (A) Contingency graphs showed the number of TP53, POLE, PIK3CA, BRAF, APC, K-Ras and CTNNB1 mutant or wild type, MSI or MSS subtype colon cancer cell lines in each sub-cluster derived from three consensuses. P values were determined by Chi-square test. (B) Box plots showed the LN-IC50 of BRAF inhibitors dabrafenib and HG6-64-1 in each sub-cluster. (C) Box plots showed the LN-IC50 of PI3K-mTOR inhibitors in each sub-cluster.